Sagent Pharmaceuticals

Sagent Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

Company Growth (employees)
Schaumburg, US
Size (employees)
440 (est)
Sagent Pharmaceuticals was founded in 2006 and is headquartered in Schaumburg, US

Sagent Pharmaceuticals Office Locations

Sagent Pharmaceuticals has an office in Schaumburg
Schaumburg, US (HQ)
1901 N. Roselle Road

Sagent Pharmaceuticals Metrics

Sagent Pharmaceuticals Financial Metrics

Sagent Pharmaceuticals's revenue was reported to be $318.3 m in FY, 2015 which is a 10% increase from the previous period.

Revenue (FY, 2015)

$318.3 m

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

$87.7 m

Gross profit margin (FY, 2015), %


Net income (FY, 2015)

($21.9 m)

EBIT (FY, 2015)

($47.1 m)

Market capitalization (29-Aug-2016)

$716.1 m

Closing share price (29-Aug-2016)


Cash (31-Dec-2015)

$29 m
Sagent Pharmaceuticals's current market capitalization is $716.1 m.
FY, 2013FY, 2014FY, 2015


$244.8 m$289 m$318.3 m

Revenue growth, %


Cost of goods sold

$167.2 m$202.8 m$230.6 m

Gross profit

$77.5 m$86.2 m$87.7 m

Gross profit Margin, %


Operating expense total

$54.1 m$67.1 m$84.7 m


$29 m$15.1 m($47.1 m)

EBIT margin, %


Interest expense

($930 k)($2.2 m)($770 k)

Pre tax profit

$30.5 m$16.2 m($48.1 m)

Income tax expense

$895 k($23.7 m)($26.2 m)

Net Income

$29.6 m$39.9 m($21.9 m)
FY, 2013FY, 2014FY, 2015


$42.3 m$55.6 m$29 m

Accounts Receivable


$6.5 m$5.6 m$7.4 m

Current Assets

$235.8 m$198.5 m$191.6 m


$57.7 m$71.2 m$19.8 m


$6 m$28.2 m$25.2 m

Total Assets

$310.2 m$381.5 m$349.7 m

Accounts Payable

$24.9 m$32.7 m$43.7 m

Total Debt

$8 m

Current Liabilities

$63.5 m$85.6 m$83.7 m

Additional Paid-in Capital

$349.3 m$353 m$367.2 m

Retained Earnings

($114.1 m)($74.2 m)($99 m)

Total Equity

$236 m$275.8 m$251.1 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.3 x1.4 x1.4 x
FY, 2013FY, 2014FY, 2015

Net Income

$29.6 m$39.9 m($21.9 m)

Depreciation and Amortization

$7.1 m$9.5 m$13.7 m

Accounts Receivable

$8.6 m($16 m)($9.3 m)


($3.5 m)$2.2 m($2.6 m)

Accounts Payable

Cash From Operating Activities

$49.6 m$23.2 m($7.5 m)

Capital Expenditures

($1.1 m)($4.2 m)($6.7 m)

Cash From Investing Activities

($97.2 m)($932 k)($22 m)

Long-term Borrowings

($9 m)($10.4 m)($471 k)

Cash From Financing Activities

$62.3 m($8.5 m)$3.5 m

Interest Paid

$652 k$1.4 m$414 k

Income Taxes Paid

$2.6 m$4.3 m

Free Cash Flow

$50.7 m$27.4 m($812 k)
Y, 2015


$2.5 m

Financial Leverage

1.4 x

Sagent Pharmaceuticals News

Sagent Pharmaceuticals Company Life

You may also be interested in